The nuclear factor (NF)-jB transcription factor has essential roles in inflammation and oncogenesis. Its ubiquitous RelA subunit is regulated by several posttranslational modifications, including phosphorylation, ubiquitination and acetylation. Ubiquitination promotes the termination of RelA-dependent transcription, but its regulation is incompletely understood. Through mass spectrometry analysis of ubiquitinated RelA, we identified seven lysines that were attached to degradative and nondegradative forms of polyubiquitin. Interestingly, lysines targeted for acetylation were among the residues identified as ubiquitin acceptor sites. Mutation of these particular sites resulted in decreased polyubiquitination. Acetylation and ubiquitination were found to inhibit each other, consistent with their use of overlapping sites. Reconstitution of rela À/À fibroblasts with wild-type and mutant forms of RelA revealed that modifications at these residues can have activating and inhibitory functions depending on the target gene context. Altogether, this study elucidates that ubiquitination and acetylation can modulate each other and regulate nuclear NF-jB function in a gene-specific manner.
Introduction
The nuclear factor (NF)-kB is a dimeric transcription factor that has essential roles in immunity and cell survival (Silverman and Maniatis, 2001; Karin and Greten, 2005) . NF-kB is formed by members of a highly conserved family of proteins that includes seven different polypeptides in mammals: RelA (also referred to as p65), c-Rel, RelB, p50 and its precursor p105, and p52 and its precursor p100. All NF-kB subunits share a B300 amino-acid region termed the Rel Homology Domain (RHD) (Hayden and Ghosh, 2008) . Canonical NF-kB activity regulates proinflammatory and prosurvival gene expression and is primarily mediated by RelA/p50 heterodimers. Non-canonical NF-kB activity, mediated primarily by RelB/p52 heterodimers, regulates the development of various immune organs and differentiation of various lymphoid cell populations.
Given its role in cell survival, abnormal activation of the NF-kB pathway is frequently encountered in cancer (Karin, 2006) . Mutations in various regulators of NF-kB have been found in several lymphoid malignancies, and NF-kB activation is also frequently found in solid tumors. Moreover, the activation of NF-kB in the setting of chronic inflammation is thought to be critically important in the subsequent development of neoplasia (Karin and Greten, 2005) . Finally, NF-kB activation participates in cancer chemo-and radioresistance (Basse`res and Baldwin, 2006) . For all these reasons, NF-kB regulation is intensely studied in the context of oncogenesis and cancer therapy.
The regulation of canonical NF-kB activation is mediated by cytosolic and nuclear events. Under basal conditions, NF-kB dimers interact with inhibitory IkB proteins and are localized in the cytosol (Baeuerle and Baltimore, 1988) . Activation of the IkB kinase results in the phosphorylation, ubiquitination and degradation of IkB (Henkel et al., 1993; Chen et al., 1995) , followed by the nuclear translocation of NF-kB dimers, ultimately leading to the induction of target genes (Silverman and Maniatis, 2001) . Although various distinct activators lead to the generation of free DNA-binding subunits, each stimulus results in the induction of a specific subset of genes with peculiar parameters to suit the specific requirements of the activation signal. Therefore, in addition to the control of nuclear translocation, this system requires further mechanisms to regulate NF-kB activity. These include the regulation of RelA activity by post-translational modifications (PTMs), such as phosphorylation (Zhong et al., 1998; Sakurai et al., 1999) , acetylation (Chen et al., 2001 ; Kiernan et al., 2003) , methylation (Ea and Baltimore, 2009; Yang et al., 2009 Yang et al., , 2010 , proline isomerization (Ryo et al., 2003) and ubiquitination (Saccani et al., 2004; Maine et al., 2007; Tanaka et al., 2007) .
Of these various PTMs, ubiquitination has been shown to favor the termination of NF-kB activity by promoting the degradation of a fraction of DNA-bound and active RelA in a gene-specific manner (Saccani et al., 2004; Natoli and Chiocca, 2008) . The ubiquitination and proteasomal degradation of RelA is stimulated by its phosphorylation downstream of the IkB kinase complex (Lawrence et al., 2005; Mao et al., 2009) . Phosphorylation of serine 468 facilitates RelA ubiquitination and degradation (Geng et al., 2009 ) by promoting its binding to GCN5, a factor that in this context serves to tether RelA to a COMMD1-Cul2 containing ubiquitin ligase (Maine et al., 2007; Mao et al., 2009) . Other potential routes for RelA ubiquitination include a SOCS1-Cul2 ligase (Ryo et al., 2003) and the nuclear protein PDLIM2 (Tanaka et al., 2007) , but whether these events are linked to the actions of IkB kinase and COMMD1 have not been fully elucidated. Moreover, whether other PTMs besides phosphorylation can modulate RelA ubiquitination is incompletely understood, but it has been suggested that acetylation and methylation may modulate RelA ubiquitination (Yang et al., 2010) . Finally, it is also unclear whether non-degradative forms of ubiquitination can modulate RelA activity.
To better understand the role of RelA ubiquitination in transcriptional control, we mapped the ubiquitin acceptor sites in this protein by mass spectrometry. We found that several of these residues overlap with lysine acetylation sites and that indeed these two modifications regulate each other. Moreover, non-degradative forms of RelA ubiquitination were also detected, suggesting that this PTM may have broader effects than the release of DNA-bound active RelA. Finally, our studies provide a picture of the complex and gene-specific effects of PTMs on these residues, including the repressive effect of RelA acetylation on a number of gene targets, a process that is likely a part of the critical chain of events that provide gene specificity to the NF-kB pathway.
Results
RelA ubiquitination is directed to the amino-terminal RHD To identify the ubiquitin acceptor residues responsible for RelA ubiquitination, we first investigated the ubiquitination of broad truncation mutants (the amino-terminal RHD or the carboxyl-terminal transactivation domains or TADs). The RHD was strongly ubiquitinated (Figure 1a , upper panels using an N-terminal-specific antibody), whereas the TAD was not ubiquitinated at all when expressed in isolation of the RHD (Figure 1a , lower panels). These findings are in keeping with the fact that COMMD1 and SOCS1 both bind to the RHD (Ryo et al., 2003; Maine et al., 2007) and suggest that the TAD fails to be ubiquitinated either as a result of a lost interaction with the ubiquitin ligase or because it lacks the lysine(s) that serve as acceptor site(s).
RelA can be targeted by non-degradative ubiquitination Although RelA ubiquitination has been shown to be stimulus dependent and affect RelA stability, only a small amount of the cellular pool of this protein is degraded in response to proinflammatory stimuli. Unlike IkB-a, whose stimulus-induced ubiquitination results in substantial degradation, RelA ubiquitination does not affect overall cellular levels of this protein and is only noticeable when specific cellular compartments are examined or when new protein synthesis is blocked (Maine et al., 2007; Geng et al., 2009; Yang et al., 2009) . All these suggested that not all RelA ubiquitination may be for degradative purposes, and thus we set out to examine whether alternative forms of ubiquitination, such as lysine-63 (K63)-linked chains, also take place. RelA was expressed together with ubiquitin, and the presence of ubiquitinated RelA was detected after enrichment of ubiquitinated proteins on nickel-nitrilotriacetic acid (NTA) columns (Figure 1b) . Using a mutant form of ubiquitin that only has the K63 site available for polyubiquitin chain formation, we found evidence that RelA can be ubiquitinated in a K63-dependent manner ( Figure 1b , left panels). Conversely, other lysine linkages were also evident, as a ubiquitin mutant lacking K63 was also able to recover polyubiquitinated RelA (Figure 1b , right panels).
To confirm these findings and exclude the recovery of mixed polyubiquitin chains containing endogenous and mutant ubiquitin, we utilized a ubiquitin replacement strategy. This was accomplished through recently developed cell lines in which endogenous ubiquitin expression is repressed by tetracycline-inducible short hairpin RNA against all four human genes encoding ubiquitin, whereas mutant ubiquitin is concurrently expressed (Xu et al., 2009) . After tetracycline induction, we immunoprecipitated RelA ( Figure 1c ) and found that ubiquitinated RelA could be recovered from cells expressing the K63R and K48R ubiquitin mutants, confirming the conjugation of RelA to non-K48-and non-K63-linked chains. Next, we utilized an antibody that is specific for K63-linked polyubiquitin chains and found that cell stimulation with tumor necrosis factor (TNF) resulted in the accumulation of polyubiquitinated RelA, and this material was immunoreactive with the K63-specific antibody (Figure 1d ).
Redundant lysines can be targeted for ubiquitination
Having identified the RHD as a potential site for ubiquitin conjugation, we undertook a mutagenesis approach to try to identify the ubiquitin-accepting residue(s). Progressive mutagenesis of all lysines in the RHD (N) failed to abrogate RelA ubiquitination (Figure 1e ). The apparent discrepancy between this result and the findings in Figure 1a , in which the RHD deletion mutant (TAD) was not ubiquitinated, suggested that the previous result was more likely related to the structural alterations inherent to the deletion rather than to the actual loss of absolutely required lysines. Moreover, we found that K/R mutations in the TAD (C) also had persistent ubiquitination. Only a mutant completely devoid of all lysines (All) was ultimately able to abrogate all RelA ubiquitination, indicating the highly redundant nature of lysines as acceptor sites for ubiquitination of this protein. RelA ubiquitination involves K63-and non-K63-linked polyubiquitin chains. RelA ubiquitination was examined as in panel a after expression of a ubiquitin mutant, in which all lysines except K63 had been mutated to arginine (K63 only), or after expression of a ubiquitin mutant, in which only K63 had been mutated to arginine, leaving all other lysines intact (K63R). RelA was detected using an antibody against the hemagglutinin tag (HA). (c) Ubiquitination of RelA by non-K48-and non-K63-linked polyubiquitin chains. U2OS cells were cultured with doxycycline for 4 days to express tetracycline (Tet)-inducible short hairpin RNAs against all the four human ubiquitin genes and Tet-inducible HA-tagged ubiquitin (WT or the lysine mutants K63R or K48R). After 3 h of treatment with MG-132 (20 mM), denaturing cell lysates were prepared and RelA immunoprecipitation was performed. The presence of ubiquitinated RelA was determined by immunoblotting for ubiquitin or HA. Similarly, ubiquitinated RelA forms were detected after short and long exposures of the RelA immunoblots. (d) RelA is K63-polyubiquitinated after TNF stimulation. HEK 293 cells transfected to express His-tagged RelA and HA-tagged ubiquitin were stimulated with TNF (2000 U/ml for 60 min) and then lysed. RelA was precipitated (Ni-NTA beads) and the material was probed with HA antibody or a K63-specific polyubiquitin antibody. (e) Only complete deficiency of lysines prevents RelA ubiquitination. Lysine residues in RelA were progressively mutated to arginine (K/R) in the N terminus (amino acids 1-218), the C terminus (amino acids 301-551) or the entire RelA polypeptide (all, amino acids 1-551). RelA ubiquitination was assessed as in b.
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Mass spectrometry identifies ubiquitin acceptor sites in the N terminus of RelA The ubiquitin acceptor sites proved to be highly redundant precluding the identification of physiological target sites using a mutagenesis approach. Therefore, we decided to utilize mass spectrometry to identify physiological acceptor sites and polyubiquitin branching in a non-biased manner. To this end, ubiquitinated RelA was purified through a sequential affinity procedure termed bimolecular affinity purification, and the recovered material was analyzed by mass spectrometry. The procedure was performed three times, and in aggregate allowed the identification of seven ubiquitin-conjugated lysines from among the 18 lysines present in RelA (Figure 2a) . Three of the ubiquitin-conjugated residues corresponded to lysines previously described as acetylation sites. In addition, these data confirmed the presence of K48-linked polyubiquitin chains as well as other linkages, including K29, K33 and K63 (data not shown).
RelA polyubiquitination overlaps with acetylation target lysines
To understand the physiological relevance of RelA ubiquitination at the sites identified, we introduced point mutations in the indicated lysines. We focused further analysis on four mutants of RelA, which are schematically displayed in Figure 2b . In the first mutant, all the four lysines not known to be acetylation targets were changed to arginines (K4R-NonAc). The other three lysines (K123, K310 and K315) have been reported to the be acetylation sites, with two of these sites (K123 and K315) being immediately adjacent to a preceding lysine (marked with an asterisk) that can also be acetylated (Chen et al., 2002; Kiernan et al., 2003; Buerki et al., 2008; Rothgiesser et al., 2010) . On the basis of this, K122 and K314 were also included in the analysis. Given that K310 has received particular attention as an acetylation site, we generated two mutants affecting the lysines targeted for acetylation excluding or including K310 (K4R and K5R, respectively). Finally, a mutant containing most of the lysines identified was also generated (K8R).
Next, we examined whether these mutations affected RelA acetylation. RelA was coexpressed with p300, the most potent acetyltransferase that targets this protein.
After RelA precipitation, the recovered material was immunoblotted with an acetyl-lysine reactive antibody. Wild-type (WT) RelA or the K4R-NonAc mutant targeting sites not known to be acetylation sites were clearly acetylated by p300 (Figure 2c ). On the other hand, the RelA K310R mutant was poorly acetylated, Figure 2 RelA polyubiquitination occurs at sites of acetylation. (a) Cartoon depicting the lysine acceptor sites identified by mass spectrometry. Residues indicated by black arrows have not been reported to be acetylated, whereas red arrows indicate residues previously noted to be acetylated. Two adjacent lysines previously also reported to be acetylated (K122 and K314) are indicated by asterisks. (b) Schematic representation of the mutants used in subsequent analysis. K4R-NonAc: mutation of lysines not known to be acetylation sites (K56, 62, 79 and 195R) ; K4R: mutation of four lysines previously noted to be acetylation sites (K122, 123, 314 and 315R); K5R: as K4R but with the additional mutation of K310 (K122, 123, 310, 314 and 315R); K8R combined mutation of eight lysine residues (K56, 62, 79, 122, 123, 195, 314 and 315R) . (c) Acetylation of RelA K4R-NonAc is not significantly affected. HA-tagged RelA mild-type (WT) or a mutant-targeting site not previously known as acetylation site (K4R-NonAc) was coexpressed with p300 in human embryonic kidney (HEK) 293 cells. RelA was subsequently precipitated from cell lysates (with an HA antibody). This material was immunoblotted with an acetyl-lysine reactive antibody (top panel) or with the HA antibody to detect RelA precipitation (middle panel). The expression of p300 in input lysates was detected by using a FLAG antibody (bottom panel). (d) Acetylation of RelA is directed to the K310 and four additional lysines previously reported. RelA mutants fused to HA were expressed in HEK 293 cells along with p300 as indicated. After cell lysis, RelA was immunoprecipitated (HA antibody) and the recovered material was immunoblotted with an acetyl-lysine reactive antibody (top panel) or was blotted for RelA (HA antibody, middle panel). Expression of p300 was confirmed in the input (FLAG antibody).
whereas the K4R mutation also showed strongly impaired RelA acetylation. The combined K5R mutation had the most dramatic reduction with nearly no detectable acetylation (Figure 2d ), indicating that these five lysines are indeed the main acetylation sites targeted by p300. Moreover, as the K310R mutation was sufficient to abrogate most acetylation, we concluded that either this site is responsible for most of the signal or that the process of acetylation requires cooperativity between the K310 site and the other lysines.
Acetylation acceptor lysines are primarily responsible for RelA polyubiquitination The ubiquitination status of these RelA mutants was examined next. RelA was coexpressed with His-tagged ubiquitin, followed by enrichment of ubiquitinated proteins on nickel-NTA beads. Western blot analysis revealed intact ubiquitination of the K4R-NonAc mutant, whereas the K4R mutant was hypo-ubiquitinated compared with the WT protein ( Figure 3a) . Additional experiments confirmed that the mutations of K122 and K314 included in the K4R mutant were required for this effect (data not shown), suggesting that they indeed function as redundant sites for both ubiquitination and acetylation.
Interestingly, the K8R mutant, which includes the acetylation sites and the four non-acetylation sites identified by mass spectrometry, was ubiquitinated to a similar extent as the WT protein. Moreover, additional lysine mutations (K8R þ K310R and others) often resulted in a paradoxical increase in RelA ubiquitination (data not shown), suggesting that extensive perturbations of RelA after multiple lysine mutations may result in polyubiquitination because of disturbed secondary and tertiary structures.
The K310R and K5R mutants were similarly examined. Expression of RelA along with His-tagged ubiquitin resulted in the upward shift of the highmolecular ladder above RelA, indicating that this laddered material corresponded to ubiquitinated RelA ( Figure 3b , first and second lanes). Although K310R showed no differences, the K4R and K5R mutants Figure 3 RelA polyubiquitination is primarily directed to acetylation sites. (a, c)Various RelA mutants were coexpressed with Histagged ubiquitin, and their ubiquitination status was assessed by precipitation and immunoblotting according to the same approach described for Figure 1b. (b) Ubiquitinated RelA was detected as a laddered high-molecular-weight material that has a shifted mobility in His-ubiquitin-transfected cells (noted on direct western blots and marked by an asterisk). (d) Mutation of the acetylation sites impairs TNF-inducible ubiquitination of RelA. Ubiquitination of RelA was detected after PD from cell lysates using the same approach described in Figure 1d .
RelA ubiquitination and acetylation H Li et al displayed reduced ubiquitination. Upon precipitation of ubiquitinated proteins, the pull down that was immunoblotted for RelA, which confirmed that K4R and K5R are hypo-ubiquitinated (Figure 3c ). The K5R mutation not only abrogated the basal ubiquitination of RelA but also led to dramatic reductions in polyubiquitination after TNF stimulation, which were evident at the level of total RelA ubiquitination and K63-linked polyubiquitination (Figure 3d ).
Polyubiquitinated RelA is not concurrently acetylated These findings indicated that lysines that are acetylation target sites are also responsible for most polyubiquitin conjugation to RelA, implicating that polyubiquitinated RelA cannot be concurrently acetylated. To test this notion, ubiquitinated RelA was purified using the bimolecular affinity purification procedure (Figure 4a ) and the acetylation of ubiquitinated RelA was examined. The acetyl-lysine-specific antibody was reactive RelA acetylation and ubiquitination compete with each other. (a) Ubiquitinated RelA is not concurrently acetylated. RelA fused to a biotinylation tag (TB) was expressed together with His-tagged human ubiquitin. In one case, RelA was purified directly from cell lysates using streptavidin agarose beads (SA). In the other case, ubiquitin-conjugated RelA was purified by first extracting ubiquitinated proteins using nickel (Ni)-NTA agarose beads and then repurifying RelA from this fraction as before (Ni-SA). The material obtained was immunoblotted for RelA (streptavidin-horseradish peroxidase) or for acetyl-lysine. Two aliquots from the SA column of increasing quantity were loaded. (b, c) RelA ubiquitination inhibits its acetylation. Glutathione S-transferase-tagged RelA (GST-RelA) was expressed along with FLAG-tagged p300. RelA ubiquitination was stimulated by increasing expression of His-tagged ubiquitin in b or by Cul2 and COMMD1 or GCN5 E575Q (acetylation-defective mutant) in c. Two days later, cells were harvested in phosphate buffered saline and lysed in a native buffer containing Triton X-100 buffer or in a denaturing buffer containing 8 M urea. The native lysate was used for RelA pull down with glutathione-agarose (GSH) beads to evaluate RelA acetylation (top panels). The denatured lysate was used for ubiquitin pull down (with Ni-NTA beads), followed by RelA immunoblotting, to assess the ubiquitination status of RelA (bottom panels). (d) RelA acetylation inhibits ubiquitination. His-tagged RelA was expressed together with increasing amounts of CBP as shown. His-tagged RelA was enriched on Ni-NTA beads, followed by immunoblotting with the indicated antibodies (the arrow points to acetylated RelA). The lower part shows the input material.
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with the non-ubiquitinated form of RelA and never produced any signal against ubiquitinated RelA, supporting the hypothesis that acetylated RelA is refractory to ubiquitination.
Ubiquitination inhibits RelA acetylation
Next, we extended these findings in vivo, in which we set out to promote RelA ubiquitination to examine its effects on the levels of acetylated RelA. The p300-dependent acetylation of glutathione S-transferasetagged RelA was monitored by precipitation and immunoblotting with an acetyl-lysine reactive antibody. We used increasing expression of His-tagged ubiquitin to drive RelA ubiquitination (Figure 4b ). This led to greater amounts of ubiquitinated RelA (Figure 4b , bottom panel) and a parallel decrease in the levels of acetylated RelA (Figure 4b, top panel) . Interestingly, this effect was observed even at the level of the nonubiquitinated form of RelA and corresponded to a progressive decrease in RelA-p300 co-precipitation ( Figure 4b , third panel), suggesting that occupation of lysines is not the only mechanism by which these two modifications compete with each other.
To substantiate these results in a complementary setting, RelA ubiquitination was promoted through two alternative approaches (Maine et al., 2007; Mao et al., 2009) : the concurrent expression of Cul2 and COMMD1 (components of the ligase complex that targets RelA), and expression of GCN5, a cofactor that binds to this ligase and promotes RelA ubiquitination (to avoid any potential cross-talk with acetylation, the E575Q acetyltransferase-deficient mutant of GCN5 was utilized). Both Cul2/COMMD1 and GCN5 promoted strong RelA ubiquitination (Figure 4c , bottom panel) and were associated with a dose-dependent reduction in RelA acetylation (Figure 4c , top panel) and reduced co-precipitation of p300 (not shown).
Increased acetylation inhibits RelA ubiquitination
These experiments indicated that ubiquitination of RelA inhibits its acetylation, and we set to examine whether the converse could be true (Figure 4d ). RelA acetylation was promoted by expression of CREB-binding protein (CBP), a homolog of p300. Increased RelA acetylation was paralleled by decreased RelA ubiquitination noted by precipitating RelA and immunoblotting for ubiquitin ( Figure 4d , top panel; also evident as high-molecularweight material in RelA western blots). Altogether, the data indicated that these two PTMs can target the same sites and antagonize each other in vivo.
Generation of rela
À/À -reconstituted fibroblasts To examine the functional contribution of RelA modification at these five lysines, mutations of these sites were introduced in the corresponding murine homolog of RelA (designated here as mRelA). It is important to note that all the lysines identified by mass spectrometry are tightly conserved among mammals, and for simplicity we will continue to refer to these sites according to their position in human RelA.
We generated K to R mutations, which abrogate all modifications of these residues while preserving the overall charge at these positions, as well as K to Q mutations, which mimic lysine acetylation. These mRelA mutants were stably expressed in rela À/À mouse embryo fibroblasts utilizing lentiviral infection. Comparable expression of the desired mutants and relevant NF-kB regulatory proteins was confirmed by immunoblotting (Figure 5a ). Expression of classical IkB proteins and other NF-kB subunits became greater upon reintroduction of mRelA, and this effect was similar across all cell lines developed. As these proteins are themselves expressed from NF-kB-responsive genes (Hayden and Ghosh, 2008) , these data suggested that the transcriptional activity of the mutants was preserved. Indeed, mRNA expression of Nfkbia, the gene encoding IkB-a, was largely similar across all cell lines (Figure 5b) RelA K/R and K/Q mutants are able to dimerize and bind DNA The RHD is required for dimerization and DNA binding, and this latter function involves indirectly K122 and K123 (Chen et al., 1998) . Thus, we examined first whether the RelA mutants could dimerize, bind to IkB-a and their cognate DNA. Immunoprecipitated mRelA from the stable cell lines demonstrated coprecipitation of endogenous p105, p50 and IkB-a (Figure 5c ), indicating that they can form heterodimers and bind to IkB-a. The K4Q and K5Q mutants displayed slight predilection for p50 compared with IkB-a binding, consistent with previous reports that acetylation has an inhibitory effect on RelA-IkB-a interactions (Chen et al., 2001) . Similarly, nuclear levels of RelA K5Q were slightly higher in unstimulated cells, whereas post-stimulation levels were comparable to WT and K5R stable cells (Supplementary Figure S1) . Next, we assessed the ability of these mutants to bind to DNA using a DNA/protein co-precipitation assay using nuclear extract and biotinylated kB-containing oligonucleotides (Figure 5d ). All mutants were coprecipitated to a similar extent by DNA in unstimulated cells (Figure 5d ) and in extracts from TNF-stimulated cells (data not shown). Altogether, the K/R or K/Q mutations did not impair dimerization or DNA binding, a prerequisite to examine the contribution of these residues to gene expression.
Lysine modifications have gene-specific roles in transcription Next, we examined the effects of modifications at these residues on global TNF-inducible gene expression in K5R-and K5Q-reconstituted fibroblasts. After filtering the data for genes regulated by at least twofold in response to TNF in WT cells, we identified 185 genes that were differentially regulated by a factor of twofold in either the K5R or K5Q cells compared with the WT cells (Figure 5e ; also see Supplementary Figure S4 for high resolution image). Contrary to our initial expectation, the acetyl-mimicking K5Q mutation did not lead to a global activation of gene expression. Rather, many TNF-inducible and RelA-dependent genes in these cells were specifically underexpressed in K5Q cells. Nevertheless, an activating effect of the K5Q mutation was also seen (lower part of the gene cluster in Figure 5e ; also see Supplementary Figure S4 for high resolution image).
Key findings from this analysis were confirmed by quantitative RT-PCR such as the dramatic repression of Vcam1, Il6 and Lamb3 expression in K5Q-reconstituted fibroblasts (Figure 6a and Supplementary Figure S2) ; the converse increase of Mmp13, Mmp9, Expi and Ccl9 in K5Q-expressing cells was also observed (Figure 6f and Supplementary Figure S2) . Moreover, similar alterations were noted for genes whose expression levels were too low to pass filter criteria of the microarray analysis such as Icam1, Saa3 and Cxcl10, which demonstrated repressed expression in K5Q cells (Figure 6b and Supplementary Figure S2) , and Mmp3, which demonstrated exaggerated late induction in K5Q cells (Supplementary Figure S2) . Inducible RelA ubiquitination can be detected on chromatin Vcam1 and Icam1 expression was evaluated in further detail by quantitative RT-PCR, which confirmed the repressive effect of RelA K5Q observed in the microarray analysis (Figures 6a and b) . In addition, the K4Q mutation was similarly repressive, whereas isolated K310 mutations had minimal effects on these and other genes examined (Vcam1, Icam1, Mmp13, Mmp3, Csf2, Saa3, Il6, Ptgs2 and Cxcl10; Figure 6 ; data not shown).
Cells reconstituted with K5R, a mutant unable to be modified on any of these residues, displayed increased expression of Vcam1 and Icam1. We initially speculated that this was due to loss of degradative ubiquitination, given the inhibitory effects of ubiquitination on Icam1 expression (Burstein et al., 2005; Maine et al., 2007; Mao et al., 2009) . However, the unexpected inhibitory effects of the K5Q mutant suggested that loss of acetylation could also account for the increased expression in the K5R-expressing fibroblasts. To clarify this question, the presence of ubiquitinated RelA at this promoter was examined by chromatin immunoprecipitation (ChIP) and re-ChIP using ubiquitin and RelA sequential immunoprecipitations. This confirmed the physiological induction of RelA ubiquitination on the human ICAM1 promoter (Figure 6c ).
Histone acetylation correlates with the transcriptional effects of K5 mutations
We next evaluated the potential mechanism(s) for the transcriptional effects of K5 mutations. ChIP analysis of the Vcam1 or the Icam1 promoters indicated that RelA recruitment was not impaired even for the repressive RelA K5Q mutant (Figures 6d and e) . In fact, the recruitment of RelA K5R and K5Q to the Icam1 promoter persisted at 5 h compared with RelA WT, consistent with their decreased ubiquitination. Similarly, recruitment of CBP to this region could not account for differences in expression (Supplementary Figure S3) . However, histone acetylation of the Vcam1 and Icam1 promoters had a general correlation with gene expression, being decreased in RelA K5Q-reconstituted fibroblasts and somewhat elevated-particularly after TNF-in RelA K5R cells (Figures 6d and e) . The converse findings were made for Mmp13, a gene that was selectively induced in RelA K5Q cells (Figure 6f ). Again, RelA or CBP recruitment did not correlate with differences in Mmp13 expression (Figure 6g and Supplementary Figure S3) . However, histone acetylation in this promoter region was dramatically increased in RelA K5Q-expressing fibroblasts, consistent with their increased expression of Mmp13 (Figure 6g ).
Discussion
The present study identifies the ubiquitination sites in the NF-kB subunit RelA. Although our mapping studies utilizing a mass spectrometry approach identified seven acceptor sites, we find that ubiquitination of this protein is promiscuous and only the elimination of all lysines abrogates ubiquitination completely. However, such extensive mutagenesis produces a non-functional protein, unable to bind DNA (data not shown). Consistent with another report (Fan et al., 2009) , the residue K195 was identified in this study as a ubiquitin acceptor site. However, we found no evidence that this site serves as the dominant or preferential site of ubiquitination. Rather, we found that four lysines that are also the acetylation target sites (K122, K123, K314 and K315) are primarily responsible for RelA polyubiquitination. Indeed, other recent studies have highlighted the importance of K314 and K315 in RelA ubiquitination, as mutation of these two residues results in increased protein stability (Yang et al., 2009) . Our studies would suggest that this result may be explained, in part, by the fact that these residues are ubiquitin acceptor sites.
Using mass spectrometry and other approaches, we demonstrate that RelA ubiquitination can involve degradative and non-degradative polyubiquitination. RelA ubiquitination has been shown to promote its release from chromatin through proteasomal degradation (Saccani et al., 2004; Burstein et al., 2005; Maine et al., 2007; Geng et al., 2009; Mao et al., 2009) , and indeed using ChIP/re-ChIP we show that TNF induces ubiquitinated RelA on the human ICAM1 promoter. Lysates from the stable cell lines described in panel a were used for mRelA immunoprecipitation (HA antibody), followed by immunoblotting for p105/p50 as well as IkB-a. (d) DNA binding is not affected in mRelA mutants. Nuclear extracts from unstimulated cells were mixed with a biotinylated double-stranded short oligonucleotide probe that was subsequently precipitated using streptavidin beads. Following elution, mRelA binding was determined by immunoblotting. (e) Identification of RelA-and K5-regulated TNF-response genes. Cells stably reconstituted with WT mRelA or K5 mutants were stimulated for 1 or 8 h with TNF (20 ng/ml) or were left untreated in two independent experiments as indicated. Total RNA was extracted and transcriptomewide microarray experiments were performed. The whole data set was filtered for transcripts that were regulated by TNF in WT-reconstituted cells by more than twofold. This data set was further filtered for genes that were differentially regulated by either K5 mutation at least twofold on average in both experiments, resulting in 185 genes of interest. Depicted is a hierarchical cluster analysis of this group of genes in which relative changes of expression levels are displayed as color-coded log 2 -transformed ratio values (see Materials and methods section for details). Ratio values from mRelA-deficient cells (vector, lanes 1-3) were not clustered but are aligned along the gene list for comparison. Gray colors indicate no measurable expression. The average of both experiments are displayed for the vector and WT control lines, whereas each replicate is shown for the K5R and K5Q cell lines. Red arrowheads point to genes evaluated further by qRT-PCR. Also see Supplementary Figure S4 for high resolution image.
The specific nature of chromatin-associated RelA ubiquitination could not be directly ascertained by ChIP/ re-ChIP because of limitations imposed by currently available reagents. Nevertheless, on the basis of the recruitment of COMMD1 and GCN5 to specific gene promoters, and the effects of these factors on RelAchromatin interactions, we believe that degradative forms of RelA ubiquitination occur, at least in part, on chromatin. The role of non-degradative RelA ubiquitination remains to be fully elucidated, but it is possible that this PTM may modulate modifications of the targeted lysines including acetylation, without necessarily triggering protein degradation (Figure 7) .
Several complementary experimental approaches provide evidence for an active interplay between ubiquitination and acetylation of RelA (Figure 7) , a phenomenon that has been previously described for other transcription factors such as p53 (Li et al., 2002) . Ubiquitination can inhibit RelA acetylation as least by two mechanisms: direct competition for lysine acceptor sites and indirectly through reduced interactions between p300 and RelA. The latter phenomenon remains K5Q  K5R  WT  K5Q  K5R  WT  K5Q  K5R  WT  K5Q  K5R   10  5  0  1 0  5  K5Q  K5R WT K5Q K5R Figure 6 The function of RelA modifications on transcription and chromatin association is gene specific. Expression of the Vcam1 (a), Icam1 (b) and Mmp13 genes (f) was examined further by quantitative RT-PCR (qRT-PCR). TNF stimulation for 1 or 8 h was used; error bars show standard deviations from three independent experiments. (c) Promoter-associated RelA ubiquitination is stimulated by TNF. Using U2OS cells with inducible replacement of endogenous ubiquitin by HA-tagged ubiquitin, we performed a ChIP/re-ChIP experiment. Ubiquitin was immunoprecipitated next (using an HA antibody), and RelA was reprecipitated after elution. The human ICAM1 promoter region surrounding the kB-site was detected by qPCR. The signal was normalized by the background precipitation (immunoglobulin (Ig) G control immunoprecipitation) and compared with the unstimulated sample (set as 1). (d, e, g) RelA recruitment and histone acetylation at the Vcam1, Icam1 and Mmp13 promoters were determined by ChIP. As before, the respective DNA regions were detected by qRT-PCR; the signal was normalized by the background precipitation (IgG control IP) and compared with the unstimulated sample (set as 1).
unexplained at this point but suggests that ubiquitinated RelA can act in trans on non-ubiquitinated RelA. In this regard, it has been previously suggested that p300 interacts simultaneously with two molecules of RelA through dual domains (Gerritsen et al., 1997) . In that model, it is conceivable that ubiquitinated RelA may prevent binding to non-modified RelA. Alternatively, ubiquitination may affect intramolecular interactions between the N and C termini of RelA, akin to the effect of serine 276 phosphorylation on p300/RelA binding (Zhong et al., 2002) .
In addition, we find that RelA acetylation can conversely decrease RelA ubiquitination. This is in agreement with the finding that Sirt1 deficiency, encoding a deacetylase that targets RelA, leads to increased RelA acetylation and concurrent decrease in RelA ubiquitination and degradation (Yang et al., 2010) . Moreover, the ability of acetylation to inhibit RelA ubiquitination may explain, in part, the original observation that RelA acetylation leads to prolonged nuclear RelA accumulation (Chen et al., 2001) , a phenomenon seen when RelA ubiquitination and degradation are impaired (Maine et al., 2007; Mao et al., 2009) . Additionally, it is conceivable that other PTMs on these lysines, such as methylation (Yang et al., 2009 (Yang et al., , 2010 , could affect RelA ubiquitination through similar mechanisms.
Finally, our studies highlight the complex interplay of modifications of these lysine residues and their effects on endogenous gene expression. Although the K310 residue clearly has an important role in RelA acetylation and accounts for most of the p300-induced signal, the effects observed on the expression of a panel of endogenous genes were less pronounced than previous observations made using luciferase reporter constructs (Chen et al., 2001 (Chen et al., , 2002 . However, modifications of the K4 lysine group appear to have more dramatic effects on gene expression. The effects of K/Q substitutions indicate that acetylation is not only an activating modification but also can inhibit the expression of many target genes, consistent with other reports (Kiernan et al., 2003) . The ultimate mechanism that links RelA acetylation to transcriptional repression in a gene-specific manner remains to be elucidated, but our data suggest that recruitment of acetylated RelA to these gene promoters can initiate a set of repressive events on the chromatin environment. For other genes that are stimulated by RelA acetylation, such as Mmp13, the converse set of events can be demonstrated. Thus, acetylation acts more as a modification that provides gene specificity to the NF-kB response rather than simply a PTM that amplifies the activation signal as has been more commonly regarded. Other modifications of these lysine residues, including ubiquitination and methylation, could potentially have similar roles in the specification of the NF-kB transcriptional response. This hypothesis is in line with recent studies documenting that RelA modifications, alone or in combination, function to direct transcription in a highly target gene-specific manner (Hoffmann et al., 2006; Hayden and Ghosh, 2008; Moreno et al., 2010) .
Materials and methods
Cell culture, transfection and generation of stable cell lines Human embryonic kidney 293 cells were obtained from ATCC (Manassas, VA, USA). Human embryonic kidney 293T cells and rela À/À mouse embryo fibroblasts were kindly provided by Maria S Soengas and Marty W Mayo, respectively. U2OS ubiquitin replacement cells were kindly provided by Zhijian Chen (Xu et al., 2009) . All cell lines were cultured in Dulbecco 0 s modied Eagle 0 s medium supplemented with 10% fetal bovine serum and L-glutamine (2 mM). A standard calcium phosphate transfection protocol was used to transfect human embryonic kidney 293 cells . The generation of stable cell lines expressing various mutant forms of RelA was achieved through lentiviral infection and antibiotic selection utilizing an FG9-based vector system as previously described (Lois et al., 2002; Mao et al., 2009; Wright and Duckett, 2009 ).
Immunoblotting and protein precipitation Cell lysate preparation, immunoprecipitations, glutathioneagarose (GSH) precipitations and immunoblotting were performed as previously described (Burstein et al., 2004 (Burstein et al., , 2005 .
Bimolecular affinity purification and mass spectrometry-based mapping of ubiquitin acceptor sites This procedure has been described in detail elsewhere (Maine et al., 2010) . Briefly, human embryonic kidney 293 cells were transfected with His 6 -tagged human ubiquitin and RelA fused to TB (a biotinylation target peptide). The cells were grown in biotin-supplemented media and after transient proteasomal blockade with MG-132 at 40 mM for 5 h (Boston Biochem; Cambridge, MA, USA), the culture was lysed in a protein denaturing buffer containing 8 M urea. Ubiquitinated RelA was isolated through sequential affinity purification using nickel-NTA and streptavidin columns (Invitrogen; Carlsbad, CA, USA). The obtained material was separated by SDSpolyacrylamide gel electrophoresis, and bands corresponding to ubiquitinated RelA were excised for tryptic digestion, liquid chromatography separation and tandem mass spectrometry. The presence of a mass shift of 114 Da (corresponding to a diglycine signature) was considered evidence of ubiquitin conjugation to a lysine residue.
Quantitative RT-PCR Cells were stimulated with 1000 u/ml of TNF (Roche; Indianapolis, IN, USA), and total RNA was extracted using the RNeasy kit (Qiagen; Valencia, CA, USA) at the indicated time points. In all, 1 mg of RNA was used for complementary DNA synthesis from Oligo (dT)20 primers using the Superscript first strand synthesis system (Invitrogen). Real-time PCR was performed using specific primers and SYBR Green ROX Mix (ABgene; Schwerte, Germany), utilizing an Applied Biosystems 7300 real-time PCR system (Carlsbad, CA, USA). Experiments were performed in triplicate, data were normalized to housekeeping genes and the relative abundance of transcripts was calculated by the comparative DDCt method. All primer sequences are available in the Supplementary Materials and Methods section.
kB-DNA co-precipitation assay Sense and antisense oligonucleotides encoding tandem kB-sites (sense strand, 3 0 -AGCTTACAAGGGACTTTCCGCTGGG GACTTTCCAGGG-5 0 ) were annealed after heating and slow cooling. The sense strand was biotinylated in the 5 position, whereas a non-biotinylated oligonucleotide was used as control. Nuclear extracts were prepared as previously described (Burstein et al., 2005) and incubated with annealed oligonucleotides for 60 min at 4 1C. The oligonucleotides were subsequently precipitated by streptavidin agarose beads and thoroughly rinsed four times before proceeding to western blot analysis.
Supplementary materials and methods
Detailed information about the plasmids, antibodies and primers utilized in this study is provided in table form as supplementary information. Similarly, detailed description of microarray analysis and chromatin immunoprecipitation is provided there.
